|[March 08, 2013]
Research and Markets: PharmaPoint Drug Evaluation Report - Keppra (Epilepsy) - Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/b9qggc/keppra_epilepsy)
has announced the addition of GlobalData's new report "Keppra (Epilepsy)
- Forecast and Market Analysis to 2022" to their offering.
PharmaPoint Drug Evaluation report, Keppra (Epilepsy) - Forecast and
Market Analysis to 2022. Epilepsy is a brain disorder characterized by
spontaneously occurring and recurrent seizures. The market is heavily
driven by the sales of antiepileptic drugs (AEDs) targeted at seizure
reduction. The AED market is currently dominated by UCB's Keppra and
GlaxoSmithKline's Lamictal. Although both drugs have experienced
significant generic erosion, they form the mainstay of epilepsy
treatment in the nine markets and will continue to have significant
market share during the forecast period.
Other key drugs include older generation AEDs such as Pfizer's Dilantin,
Abbott's Depakote, and Novartis' egretol and Trileptal which still have
significant usage due to their longevity in the market. However, the AED
dominance landscape will continue to shift towards newer generation
drugs particularly following the recent market entry of
GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer
first-in-class mechanisms of action.
Keppra (levetiracetam) is an approved first-in-class AED developed and
marketed by UCB. The drug received FDA approval in November 1999, and EU
approval in September 2000. Levetiracetam is also marketed under the
brand E Keppra in Japan. Keppra is formulated as film-coated tablets, as
a solution for oral administration, and as a solution concentrate for
infusion. It has been the most successful of all the newer AEDs
introduced in the last 20 years, and its blockbuster sales have
propelled the relatively small Belgian pharmaceutical company UCB into
the big leagues (Shorvon, 2009).
Levetiracetam works by selectively binding to SV2A. SV2A is involved in
the release of neurotransmitters, and binding it may help reduce
excessive neurotransmitter release and stabilize electrical activity in
the brain, thus preventing seizures. Kepprahas action against many types
of generalized as well as partial seizures, and has also been shown to
be effective in some patients in whom other drugs are ineffective.
Unlike many AEDs, Keppra has an alerting rather than a sedating effect,
which may contribute to its popularity (Shorvon, 2009).
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Keppra (levetiracetam)
For more information visit http://www.researchandmarkets.com/research/b9qggc/keppra_epilepsy
Source (News - Alert): GlobalData
[ Back To Technology News's Homepage ]